Plasma proteomics identifies CRTAC1 as a biomarker for osteoarthritis severity and progression
Authors' conclusion
CRTAC1 was the most compelling and robust biomarker for OA severity and progression.
Study context
- Population
- Rotterdam Study participants184 plasma proteins measured
- Participants
- 3,517 participants
- Outcome
- Radiographic OA severity (knee, hip, hand; composite overall OA burden score) and progression
Methodological detailsplasma proteomics, Olink inflammation and cardiometabolic panels, multivariable regression adjusted for age, sex, cell counts and BMI
- Plasma proteomics
- Olink inflammation and cardiometabolic panels
- Multivariable regression adjusted for age, sex, cell counts and BMI
Main finding
As reported in the abstract
Overall OA burden (Kellgren-Lawrence sum score), CRTAC1 per 1 SD increase
Increase in overall OA Kellgren-Lawrence sum score per 1 SD increase in CRTAC1
0.09
95% CI 0.06, 0.12P = 2.9 × 10-8
Proteins significantly associated with overall OA burden
18
Proteins significant after multiple testing correction (CRTAC1, cartilage oligomeric matrix protein (COMP), thrombospondin 4, IL-18R1, TNF ligand superfamily member 14)
5
Observational data: associations, not effects.
Further findings
Knee OA progression
- CRTAC1, COMP, thrombospondin 4 and TNF ligand superfamily member 14 also associated with knee OA progression; IL-18R1 not
CRTAC1 and OA severity per joint
- CRTAC1 associated with OA severity in all three joints and knee OA progression, independent of BMI; stronger association than COMP
Original publication
Plasma proteomics identifies CRTAC1 as a biomarker for osteoarthritis severity and progression. Rheumatology (Oxford). Published 4 August 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →